Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD2 | Q9Y5L3 | 3/20 | 0.61 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012375 | 1.00 | ENTPD2 (0.61) | ENTPD2ENTPD1ENPP2DGAT2ADORA3 | |
| SCHEMBL3020317 | 0.90 | ENTPD2 (0.60) | ENTPD2ENTPD1ENPP2DGAT2ADORA3 | |
| SCHEMBL3020321 | 0.90 | ENTPD2 (0.60) | ENTPD2ENTPD1ENPP2DGAT2ADORA3 | |
| SCHEMBL14386949 | 0.89 | ENTPD2 (0.78) | ENTPD2ENTPD1ADORA3ADORA2BADORA1 | |
| SCHEMBL13211013 | 0.89 | ENTPD2 (0.78) | ENTPD2ENTPD1ADORA3ADORA2BADORA1 | |
| SCHEMBL3018892 | 0.89 | ENTPD2 (0.57) | ENTPD2ENTPD1ENPP2DGAT2ADORA3 | |
| SCHEMBL3018891 | 0.89 | ENTPD2 (0.57) | ENTPD2ENTPD1ENPP2DGAT2ADORA3 | |
| SCHEMBL13211022 | 0.85 | ENTPD2 (0.79) | ENTPD2ENTPD1 | |
| SCHEMBL15859418 | 0.85 | ENTPD2 (0.79) | ENTPD2ENTPD1 | |
| SCHEMBL3020107 | 0.85 | ENTPD2 (0.79) | ENTPD2ENTPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2019834-B1 | ECTONUCLEOTIDASE INHIBITORS | UNIV BONN (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | ENTPD2 10/4885ENTPD1 3/4885ENPP2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.